₹ 614.49 Cr
2.28%
BSE Healthcare TRI
INF251K01VD9
1000.0
1000.0
500
Mr. Sanjay Chawla
| Fund Performance | 1Y (%) | 3Y (%) | 5Y (%) |
|---|---|---|---|
| Baroda BNP Paribas Health and Wellness Fund Regular IDCWPayout | - | - | - |
| Benchmark | - | - | - |
Equity
Debt
Others
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
| Company | Holdings (%) |
|---|---|
| SUN PHARMACEUTICAL INDUSTRIES LTD. EQ NEW F.V. RE.1/- | 10.64 |
| Clearing Corporation of India Ltd | 7.88 |
| DIVIS LABORATORIES LIMITED EQ NEW RS. 2/- | 7.64 |
| MANKIND PHARMA LIMITED EQ NEW FV RE. 1/- | 7.53 |
| APOLLO HOSPITALS ENTERPRISE LIMITED EQ NEW F.V. RS.5/- | 6.03 |
| CIPLA LIMITED EQ NEW FV RS.2/- | 5.44 |
| MAX HEALTHCARE INSTITUTE LIMITED EQ | 5.44 |
| ABBOTT INDIA LIMITED EQ | 4.29 |
| ASTER DM HEALTHCARE LIMITED EQ | 4.08 |
| TORRENT PHARMACEUTICALS LIMITED EQ NEW FV RS.5/- | 3.81 |
| Sector | Holdings (%) |
|---|---|
| Healthcare | 90.54 |
| Financial Services | 2.81 |
| Consumer Services | 1.42 |